Loading..

FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
14/11/2022
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransConTM PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
13/03/2022
Ascendis Pharma A/S Receives European Approval for TransConTM hGH for Pediatric Growth Hormone Deficiency
13/01/2022
每周给药一次注射用隆培促生长素(当地商品名:SKYTROFA®,国内商品名正在注册中)于美国当地时间8月25日宣布获得美国食品和药品监督管理局(FDA)批准,用于治疗一岁以上…
26/08/2021
Prev
1
Next